lipoglycopeptide

Dalbavancin (BI-397), a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE),Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg mL and 0.25 μg mL, respectively

Dalbavancin hydrochloride (MDL-63397 hydrochloride), a semisynthetic lipoglycopeptide antibiotic, demonstrates potent bactericidal effects against Gram-positive bacteria. It effectively inhibits Staphylococcus aureus and Bacillus anthracis with minimum inhibitory concentrations (MIC 90) of 0.06 μg mL and 0.25 μg mL, respectively [1] [2].

Teicoplanin sodium (Antibiotic MDL-507 sodium) is a potent lipoglycopeptide antibiotic . Teicoplanin sodium shows antiviral activity for HIV-1 , SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity [1] [2] .

Arylomycin B6 is a lipoglycopeptide antibiotic (antibiotic) effective against Gram-positive bacteria.

Ramoplanin is an antibiotic extracted from Actinoplanes spp., a topical lipoglycopeptide antibacterial agent that inhibits gram-positive bacteria by binding to a critical lipid II intermediate, preventing peptidoglycan formation in the cell wall.